MAPT and Alzheimer disease: The failure of more than 200 clinical trials targeting Aβ and tau pathology in the past decade [6] has necessitated a paradigm shift toward understanding modifiable risk factors, particularly the emerging role of gut–brain axis dysregulation in AD pathogenesis.